Find a Tender · Contract

Cytokine Modulators

A public procurement published by The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS") via Find a Tender.

Find a TenderContract
Award value
Tender value
12
Suppliers
19
Awards
1
Notices
Contract
Stage

Overview

Supply of Cytokine Modulators to NHS Scotland which is used to treat licensed indications. Etanercept Infliximab Adalimumab Methotrexate The Goods have been split into eight (8) categories, each of which are identified as a “Lot”. Full details of each Lot are contained in section II.2 of this notice.

Key details

Source
Find a Tender
Lifecycle stage
Contract
Status
complete
CPV classification
33600000 — Pharmaceutical products
Currency
GBP
Total award value
Tender value
First published
11 Feb 2021
Last updated
11 Feb 2021
View the original notice

Awards

19 awards recorded on this procurement.

Notice timeline

Every published notice in this procurement's lifecycle.

  1. Award,contractCytokine Modulators

All suppliers

Frameworks & programmes

More from The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")

FAQs about this procurement

Who is the buyer for "Cytokine Modulators"?

Cytokine Modulators is a UK public-sector procurement published by The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS") via Find a Tender.

Has "Cytokine Modulators" been awarded?

Yes — 19 awards are recorded. The current lifecycle stage is "Contract".

Which suppliers are involved in "Cytokine Modulators"?

12 suppliers are linked: Sandoz Ltd, Pfizer Ltd, Biogen Idec Ltd., Merck Sharp & Dohme, Celltrion Healthcare United Kingdom Limited, AbbVie Ltd, amgen ltd, Fresenius Kabi Limited.

When was "Cytokine Modulators" published?

It was first published on 11 Feb 2021 and last updated on 11 Feb 2021, across 1 notice.

Track procurements like this one

Enable monitors the entire UK public-contract pipeline — get alerts on buyers, suppliers and frameworks that matter to you.

Get in touch with Enable